CLR457
Total Payments
$43,128
Transactions
3
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $33,753 | 2 | 0 |
| 2017 | $9,375 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $43,128 | 3 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I DOSE FINDING STUDY OF ORAL LTT462 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS HARBORING MAPK PATHWAY ALTERATIONS | Novartis Pharmaceuticals Corporation | $33,753 | 0 |
| A PHASE I AND OR II MULTICENTER OPEN LABEL STUDY OF CLR457 ADMINISTERED ORALLY IN ADULT PATIENTS WITH ADVANCED SOLID MALIGNANCIES | Novartis Pharmaceuticals Corporation | $9,375 | 0 |
Top Doctors Receiving Payments for CLR457
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $43,128 | 3 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $43,128
- Total Doctors 0
- Transactions 3
About CLR457
CLR457 is a drug associated with $43,128 in payments to 0 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $33,753 was paid across 2 transactions to 0 doctors.
The most common payment nature for CLR457 is "Unspecified" ($43,128, 100.0% of total).
CLR457 is associated with 2 research studies, including "A PHASE I DOSE FINDING STUDY OF ORAL LTT462 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS HARBORING MAPK PATHWAY ALTERATIONS" ($33,753).